Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions

被引:1
|
作者
Kazarian, Austin G. [1 ]
Chawla, Neal S. [2 ]
Muddasani, Ramya [2 ]
Pal, Sumanta K. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
Renal cell carcinoma; adjuvant chemotherapy; cytokines; molecular targeted therapy; precision medicine; BLIND PHASE-III; HIGH-RISK; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; TRIAL; INTERLEUKIN-2; STAGE; RECURRENCE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.3233/KCA-200105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [41] Current status and future perspective of immunotherapy for renal cell carcinoma
    Blas, Leandro
    Monji, Keisuke
    Mutaguchi, Jun
    Kobayashi, Satoshi
    Goto, Shunsuke
    Matsumoto, Takashi
    Shiota, Masaki
    Inokuchi, Junichi
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1105 - 1114
  • [42] Current status and future directions in couple therapy
    Snyder, DK
    Castellani, AM
    Whisman, MA
    ANNUAL REVIEW OF PSYCHOLOGY, 2006, 57 : 317 - 344
  • [43] CURRENT STATUS AND FUTURE DIRECTIONS IN ANTIPLATELET THERAPY
    Krakat, J.
    Mousa, S.
    Root, R.
    Mousa, S. S.
    DRUGS OF THE FUTURE, 2009, 34 (01) : 27 - 41
  • [44] Photodynamic Therapy: Current Status and Future Directions
    Benov, Ludmil
    MEDICAL PRINCIPLES AND PRACTICE, 2015, 24 : 14 - 28
  • [45] Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
    Govindarajan, Ameish
    Castro, Daniela V.
    Zengin, Zeynep B.
    Salgia, Sabrina K.
    Patel, Jalen
    Pal, Sumanta K.
    CANCERS, 2022, 14 (09)
  • [46] Cognitive Therapy: Current Status and Future Directions
    Beck, Aaron T.
    Dozois, David J. A.
    ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 : 397 - 409
  • [47] Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
    Buller, Dylan M.
    Antony, Maria
    Ristau, Benjamin T.
    ONCOTARGETS AND THERAPY, 2023, 16 : 49 - 64
  • [48] Adjuvant Therapy in Renal Cell Carcinoma-Past, Present, and Future
    Janowitz, Tobias
    Welsh, Sarah J.
    Zaki, Kamarul
    Mulders, Peter
    Eisen, Tim
    SEMINARS IN ONCOLOGY, 2013, 40 (04) : 482 - 491
  • [49] Dosing pattern of renal replacement therapy in acute renal failure: Current status and future directions
    Schiffl, H
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2006, 11 (04) : 178 - 182
  • [50] Adjuvant therapy for renal cell carcinoma
    Naomi B. Haas
    Robert Uzzo
    Current Oncology Reports, 2008, 10 : 245 - 252